Denali Therapeutics Inc (NASDAQ: DNLI) kicked off on Monday, up 6.23% from the previous trading day, before settling in for the closing price of $26.15. Over the past 52 weeks, DNLI has traded in a range of $14.56-$32.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 264.19%. While this was happening, its average annual earnings per share was recorded -138.87%. With a float of $119.11 million, this company’s outstanding shares have now reached $138.39 million.
Let’s determine the extent of company efficiency that accounts for 445 employees. In terms of profitability, gross margin is 102.8%, operating margin of 163.02%, and the pretax margin is 138.14%.
Denali Therapeutics Inc (DNLI) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 16.80%, while institutional ownership is 84.08%. The most recent insider transaction that took place on Oct 18 ’24, was worth 1,107,600. In this transaction President and CEO of this company sold 40,000 shares at a rate of $27.69, taking the stock ownership to the 235,807 shares. Before that another transaction happened on Oct 18 ’24, when Company’s Director proposed sale 40,000 for $27.42, making the entire transaction worth $1,096,800.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.72 earnings per share (EPS), higher than consensus estimate (set at -0.8) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -138.87% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Take a look at Denali Therapeutics Inc’s (DNLI) current performance indicators. Last quarter, stock had a quick ratio of 12.46. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3131.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.60 in the next quarter and is forecasted to reach -2.56 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Looking closely at Denali Therapeutics Inc (NASDAQ: DNLI), its last 5-days average volume was 0.5 million, which is a drop from its year-to-date volume of 1.08 million. As of the previous 9 days, the stock’s Stochastic %D was 43.72%. Additionally, its Average True Range was 1.07.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 64.89%, which indicates a significant decrease from 89.61% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.97% in the past 14 days, which was higher than the 50.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.17, while its 200-day Moving Average is $21.64. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $28.31. Second resistance stands at $28.84. The third major resistance level sits at $29.88. If the price goes on to break the first support level at $26.74, it is likely to go to the next support level at $25.70. Should the price break the second support level, the third support level stands at $25.17.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
The company with the Market Capitalisation of 3.98 billion has total of 142,609K Shares Outstanding. Its annual sales at the moment are 330,530 K in contrast with the sum of -145,220 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -99,030 K.
